Postmarket Study to Evaluate Biovance® in Diabetic Foot Ulcers

Status unconfirmed · Not applicable

Conditions studied: Diabetic Foot Ulcers

In brief

The purpose of this study is to compare the wound closure outcomes of subjects receiving diabetic foot ulcer treatment with and without the use of Biovance®.

Key facts

Study ID

NCT02506452

Run by

Alliqua BioMedical, Inc

People needed

51

Starts

2015-06-01

Expected to finish

2017-12-01

Last updated by the study team

2017-05-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• The subject has:
• been diagnosed with Diabetes Mellitus (insulin or non-insulin dependent) and peripheral neuropathy (loss of protective sensation) in affected foot
• a HbA1c of less than 10% assessed within last 12 weeks
• a full-thickness diabetic neuropathic foot ulcer that is free from tunnels/sinus tracks, necrotic tissue, exposed bone and/or tendon, and osteomyelitis post debridement (Wagner 1 or 2; Appendix I)
• one (target) diabetic neuropathic foot ulcer of less than 12 months duration that has an area that measures ≥ 1.5 and ≤ 10 cm2 post debridement (max length x max width) at screening that is on any surface and part of the foot (fore-, mid- or hind-foot) with an etiology related to loss of protective sensation in that foot.
• a target ulcer that closed <30% during the 2 week run-in period (2 weeks management with SOC following signature of informed consent prior to potential randomization)
• sufficient arterial supply to affected foot tested within the past 60 days

You may not qualify if…

• The subject has:
• ulcers of non-diabetic etiology on the study foot
• a target ulcer clinically infected or has underlying osteomyelitis at time of study treatment initiation
• clinical evidence of gangrene on any part of the affected foot
• a target ulcer with exposed bone or tendon
• any malignancy or a neoplasm at the target ulcer site
• active Charcot Foot or Charcot Foot that is unable to be offloaded (stable, non-active Charcot deformity that is able to be offloaded is acceptable)
• more than 3 ulcers on the study foot, including the target ulcer, and all other ulcers must be at least 3 cm removed from the target ulcer
• any significant comorbid disease that may interfere with wound healing
• received chemotherapy, radiotherapy, immunosuppressant or corticosteroid (greater than 10 mg prednisone-equivalent per day) within the past 30 days.
• had the diabetic foot ulcer treated with an experimental drug/biologic/device, or a live-cell therapy (experimental or marketed), or active moist wound healing therapy within 30 days of randomization day

Where it is running

• Institute of Advanced Wound Healing — Montgomery, Alabama, United States
• Banner Health — Phoenix, Arizona, United States
• Limb Preservation Platform — Fresno, California, United States
• Southern California Institute for Research and Education (VA) — Long Beach, California, United States
• Foot and Ankle Clinic — Los Angeles, California, United States
• Georgetown University — Washington D.C., District of Columbia, United States
• First Coast Cardiovascular Institute — Jacksonville, Florida, United States
• St. Luke's Roosevelt Hospital Center — New York, New York, United States
• Foot and Ankle Center at Coordinated Health — Bethlehem, Pennsylvania, United States
• University of Tennessee Health Sciences Center — Memphis, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.